Praziquantel (pyrazinoisoquinolone) in active cerebral cysticercosis.
A prospective open therapeutic study on volunteers with active neurocysticercosis using pyrazinoisoquinolone (Praziquantel) has shown that it is a safe and effective drug. Objective assessment of the effect of treatment was by high resolution sequential computed tomographic scanning. Sixty-six patients received the drug. Forty-one records were available for complete analysis at the end of 1 year of follow-up. The concomitant use of steroids reduced side effects significantly. A 98% improvement was achieved.
van Dellen
J R
JR
Department of Neurosurgery, Wentworth Hospital, Durban, South Africa.
McKeown
C P
CP
D000293:Adolescent; D000328:Adult; D001927:Brain Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D003551:Cysticercosis / Q000000981:diagnostic imaging / Q000188:drug therapy*; D003907:Dexamethasone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D011223:Praziquantel / Q000009:adverse effects / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
D011223:Praziquantel; D003907:Dexamethasone